about
Exosome-Mediated Metastasis: From Epithelial-Mesenchymal Transition to Escape from ImmunosurveillancePharmacogenetic versus clinical dosing of warfarin in individuals of Chinese and African-American ancestry: assessment using data simulation.UGT1A6 polymorphisms modulated lung cancer risk in a Chinese population.Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRICombinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study.Manganese Superoxide Dismutase Expression Regulates the Switch Between an Epithelial and a Mesenchymal-Like Phenotype in Breast CarcinomaPhase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer.High expression of intratumoral stromal proteins is associated with chemotherapy resistance in breast cancer.Pharmacologic modulation strategies to reduce dose requirements of anticancer therapy while preserving clinical efficacy.Targeting transcription factor STAT3 for cancer prevention and therapy.UGT1A1 Mediated Drug Interactions and its Clinical Relevance.MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.Nimbolide-Induced Oxidative Stress Abrogates STAT3 Signaling Cascade and Inhibits Tumor Growth in Transgenic Adenocarcinoma of Mouse Prostate Model.Lack of somatic ErbB2 tyrosine kinase domain mutations in hepatocellular carcinoma.A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.Role of computed tomography imaging in predicting response of nasopharyngeal carcinoma to definitive radiation therapy.Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynxPharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patientsFamilial nasopharyngeal carcinoma in a cohort of 200 patientsSimultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric methodSequential external beam radiotherapy and high-dose-rate intracavitary brachytherapy in T1 and T2 nasopharyngeal carcinoma: an evaluation of long-term outcomeQuantification of L-ergothioneine in human plasma and erythrocytes by liquid chromatography-tandem mass spectrometryA common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinomaTargeting codon 158 p53-mutant cancers via the induction of p53 acetylation
P50
Q28275420-98E78D81-7D82-4DFF-9A40-C9CD3B224909Q30984242-2DC4E31F-8ED0-4339-B8E7-E0BAAD0FD649Q34389021-338D4EFC-8E2E-4E70-8BAB-DF505B102546Q34529131-B209B94E-119F-4314-BFD4-488DC88BA814Q35903844-F69A7451-6CEE-4481-A410-A9C85FDAA2F5Q36557486-5E75C926-76DB-4397-B400-4F2DF880C3BBQ36622084-1F558398-DD5B-4707-AFF4-9BC8A1448D23Q37190619-7D0E8D6D-1F85-4C4B-B879-0B02B2671976Q37665580-0F43AAAF-7F45-4F5B-950F-C613ED0A7698Q37688210-F3DC8E7F-53B7-4DE2-8FE2-DA4BCDF8C588Q38024126-9491EFE4-E449-44CB-9DF8-911864B2AC86Q38610564-744962AB-DF3D-46C3-B4A2-50B40588F22BQ38622942-51013F6C-A85D-4AA8-A8D9-32DDE3E8B0F8Q38879231-3522BC5C-F3DB-42FF-BC47-B2B8C35AC3ACQ40230015-593BB7B8-06A9-4CEE-978A-7EA869BFFD85Q45363987-9A383981-5877-4440-B31F-2A45ADAAF0A2Q49156055-5E3FE878-D56F-4E68-B22A-46D68EE1F38CQ52532880-6889D56F-780A-42CE-94F2-B0633D190BE7Q53541080-209F324A-B2C1-4DE7-BBD0-6C84B635C6E4Q75228281-CE59BE01-072B-4EDE-9E08-BEB44F24AAA8Q80102174-41047E7C-F70E-4C97-BB12-4DAE38D09801Q82273104-8EEFFFD4-2DDC-4997-B18E-7DD8A1B36699Q83275987-280EF7FA-F967-4B43-A797-B7287E28A379Q83878226-D4EAEF78-D486-442A-8F15-0F96E26ECC07Q86392272-F9F0CC0F-7ECA-4E13-852C-31B01B3F99B6Q90664296-A21FF7ED-5492-422E-81B0-0750DB984B28Q94461581-1649C444-8EED-43D2-BBAF-496125389E65
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Boon Cher Goh
@ast
Boon Cher Goh
@en
Boon Cher Goh
@es
Boon Cher Goh
@nl
Boon Cher Goh
@sl
type
label
Boon Cher Goh
@ast
Boon Cher Goh
@en
Boon Cher Goh
@es
Boon Cher Goh
@nl
Boon Cher Goh
@sl
prefLabel
Boon Cher Goh
@ast
Boon Cher Goh
@en
Boon Cher Goh
@es
Boon Cher Goh
@nl
Boon Cher Goh
@sl
P106
P31
P496
0000-0002-4107-102X